SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 124 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,437,012 | -30.2% | 98,969 | +0.7% | 0.00% | 0.0% |
| Q2 2023 | $2,057,377 | +107110.9% | 98,298 | +8.2% | 0.00% | 0.0% |
| Q1 2023 | $1,919 | -6.4% | 90,854 | +12.8% | 0.00% | -33.3% |
| Q4 2022 | $2,050 | -99.9% | 80,568 | +2.3% | 0.00% | 0.0% |
| Q3 2022 | $1,893,000 | +38.1% | 78,788 | +10.6% | 0.00% | +50.0% |
| Q2 2022 | $1,371,000 | +35.5% | 71,266 | +22.4% | 0.00% | +100.0% |
| Q1 2022 | $1,012,000 | -18.5% | 58,239 | +2.7% | 0.00% | -50.0% |
| Q4 2021 | $1,242,000 | +13.0% | 56,723 | -1.3% | 0.00% | +100.0% |
| Q3 2021 | $1,099,000 | +15.6% | 57,499 | +3.8% | 0.00% | 0.0% |
| Q2 2021 | $951,000 | +33.9% | 55,399 | +74.4% | 0.00% | 0.0% |
| Q1 2021 | $710,000 | -2.3% | 31,768 | -2.8% | 0.00% | 0.0% |
| Q4 2020 | $727,000 | +60.1% | 32,693 | +6.4% | 0.00% | 0.0% |
| Q3 2020 | $454,000 | -9.2% | 30,726 | -8.9% | 0.00% | 0.0% |
| Q2 2020 | $500,000 | +93.8% | 33,744 | +43.8% | 0.00% | 0.0% |
| Q1 2020 | $258,000 | +27.7% | 23,474 | +1.8% | 0.00% | – |
| Q4 2019 | $202,000 | +18.1% | 23,054 | +0.9% | 0.00% | – |
| Q3 2019 | $171,000 | -20.1% | 22,851 | -0.6% | 0.00% | – |
| Q2 2019 | $214,000 | +111.9% | 22,991 | +19.3% | 0.00% | – |
| Q1 2019 | $101,000 | +17.4% | 19,265 | -0.7% | 0.00% | – |
| Q4 2018 | $86,000 | -24.6% | 19,410 | +38.1% | 0.00% | – |
| Q3 2018 | $114,000 | +10.7% | 14,060 | -4.3% | 0.00% | – |
| Q2 2018 | $103,000 | – | 14,685 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |